Compare VanEck Gold Miners ETF (GDX) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Revvity Inc — how do they compare? VanEck Gold Miners ETF trades at $89.28 (market cap $25.65B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: VanEck Gold Miners ETF is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Revvity Inc for 12 Days on average.
| GDX | RVTY | |
|---|---|---|
Market Cap | $25.65B | $16.98B |
Volume | 16,534,046 | 1,456,900 |
52-Week High | $115.84 | $157.36 |
52-Week Low | $68.28 | $82.26 |
Typical Hold Time | 76 Days | 12 Days |
Sector | — | Health |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX (VanEck Gold Miners ETF) trades at $86.74, up 1.5% on the day but facing bearish technical signals with 15 sell indicators versus 4 buy signals. The ETF remains 22% below its peak despite gold trading near $4,270, creating a potential catch-up opportunity. Recent institutional activity shows mixed sentiment with some firms reducing positions while others increased stakes significantly.
The outlook remains cautious with technical indicators pointing bearish, though gold's resilience amid rising rates provides fundamental support. Key risks include interest rate sensitivity and metals price volatility, while the valuation gap between physical gold and miners presents a potential opportunity if gold maintains strength.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
